Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models

The tyrosine kinase inhibitor (TKI) imatinib has transformed the treatment and outlook of chronic myeloid leukemia (CML); however, the development of drug resistance and the persistence of TKI-resistant stem cells remain obstacles to eradicating the disease. Inhibition of proteasome activity with bo...

Descripción completa

Detalles Bibliográficos
Autores principales: Crawford, L J, Chan, E T, Aujay, M, Holyoake, T L, Melo, J V, Jorgensen, H G, Suresh, S, Walker, B, Irvine, A E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3940921/
https://www.ncbi.nlm.nih.gov/pubmed/24590311
http://dx.doi.org/10.1038/oncsis.2014.3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3940921/
https://www.ncbi.nlm.nih.gov/pubmed/24590311
http://dx.doi.org/10.1038/oncsis.2014.3

Ejemplares similares